Oxaliplatin

Generic Name: Oxaliplatin

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₈H_₁₄N_₂O_₄Pt

CAS Number: 61825-94-3

Unique Ingredient Identifier: 04ZR38536J

Background: Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemic...

Indication: Oxaliplatin, in combination with infusional fluorouracil and leucovorin, is indicated for the treatment of advanced colorectal cancer and adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor.

Associated Conditions: Advanced Colorectal Cancer, Stage III Colon Cancer

Associated Therapies: -

Clinical Trials

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

Phase 3

Recruiting

Conditions: Metastatic Colorectal Carcinoma
Metastatic Malignant Neoplasm in the Liver
Stage IV Colorectal Cancer AJCC v8
Unresectable Colorectal Carcinoma

Interventions: Biological: Cetuximab
Biological: Bevacizumab
Procedure: Computed Tomography
Drug: Floxuridine
Drug: Fluorouracil
Procedure: Implantation
Drug: Irinotecan
Procedure: Intrahepatic Infusion Procedure
Drug: Leucovorin
Drug: Oxaliplatin
Biological: Panitumumab
Procedure: Single Photon Emission Computed Tomography

First Posted Date: 2023-05-17

Last Posted Date: 2024-11-05

Lead Sponsor: ECOG-ACRIN Cancer Research Group

Target Recruit Count: 408

Registration Number: NCT05863195

Locations: 🇺🇸
UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States
🇺🇸
UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
🇺🇸
UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States

and more 36 locations

Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer

Phase 2

Recruiting

Conditions: PD-L1 Gene Amplification
FGFR2 Amplification
Metastatic Gastric Cancer

Interventions: Drug: Nivolumab
Drug: Capecitabine
Drug: Oxaliplatin

First Posted Date: 2023-05-16

Last Posted Date: 2024-01-02

Lead Sponsor: Kidney Cancer Research Bureau

Target Recruit Count: 23

Registration Number: NCT05859477

Locations: 🇺🇸
Bureau for Cancer Research, New York, New York, United States

A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

Phase 1

Recruiting

Conditions: Biliary Cancer
Bile Duct Cancer
Cancer of the Bile Duct

Interventions: Drug: oxaliplatin
Drug: capecitabine
Biological: Keytruda
Biological: CDX-1140

First Posted Date: 2023-05-09

Last Posted Date: 2024-12-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT05849480

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Study of AK119 and AK 112 With or Without Chemotherapy for Colorectal Cancer Patients

Phase 1

Not yet recruiting

Conditions: Colorectal Cancer

Interventions: Drug: AK119
Drug: AK112
Drug: Oxaliplatin
Drug: Irinotecan
Drug: Calcium folinate
Drug: Fluorouracil

First Posted Date: 2023-05-06

Last Posted Date: 2023-05-06

Lead Sponsor: Akeso

Target Recruit Count: 72

Registration Number: NCT05846867

Locations: 🇨🇳
Cancer Hospital Affiliated to Harbin Medical University, Harbin, China

Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer

Phase 2

Recruiting

Conditions: Colorectal Cancer

Interventions: Drug: cadonilimab
Drug: irinotecan
Drug: Oxaliplatin
Drug: leucovorin or levoleucovorin
Drug: 5-FU

First Posted Date: 2023-05-03

Last Posted Date: 2023-11-15

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 20

Registration Number: NCT05839470

Locations: 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China

Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

Phase 2

Active, not recruiting

Conditions: Clinical Stage II Gastric Cancer AJCC v8
Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage III Gastric Cancer AJCC v8
Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IVA Gastric Cancer AJCC v8
Clinical Stage I Gastric Cancer AJCC v8
Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions: Biological: Atezolizumab
Procedure: Biospecimen Collection
Drug: Capecitabine
Procedure: Computed Tomography
Drug: Docetaxel
Procedure: Echocardiography
Drug: Fluorouracil
Drug: Leucovorin Calcium
Procedure: Lymphadenectomy
Procedure: Magnetic Resonance Imaging
Drug: Oxaliplatin
Procedure: Positron Emission Tomography
Procedure: Surgical Procedure

First Posted Date: 2023-05-01

Last Posted Date: 2024-12-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 240

Registration Number: NCT05836584

Locations: 🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸
Kaiser Permanente Dublin, Dublin, California, United States

and more 133 locations

XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer

Phase 2

Recruiting

Conditions: Rectal Cancer
MSS

Interventions: Drug: Cadonilimab
Drug: Oxaliplatin
Drug: Capecitabine

First Posted Date: 2023-04-18

Last Posted Date: 2023-04-18

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 92

Registration Number: NCT05815303

Locations: 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China